

Colgate-Palmolive vs Kimberly-Clark
Global oral care and household products leader vs Global maker of tissue and personal care products. Which is the better buy for your portfolio in June 2026? Plain-English answer below.
Colgate-Palmolive defends global oral care and personal hygiene franchises with pricing power that's proven resilient through multiple inflationary cycles while Kimberly-Clark sells diapers, tissues, and professional hygiene products to consumers who buy out of necessity but will trade down to private label when budgets tighten. Both are consumer staples companies leaning on brand strength and distribution scale to hold shelf space in a world where retailer private label competition keeps intensifying. Colgate-Palmolive vs Kimberly-Clark reveals where premium pricing holds, where private label substitution erodes volume, and which franchise's organic revenue growth and margin trajectory looks more resilient into the next cost cycle.
Colgate-Palmolive defends global oral care and personal hygiene franchises with pricing power that's proven resilient through multiple inflationary cycles while Kimberly-Clark sells diapers, tissues, ...
Why It’s Moving

Colgate-Palmolive is sliding on valuation worries as analysts flag limited upside and a possible 8% downside.
- Recent analyst commentary has been mixed to mildly positive overall, but the spread between the highest and lowest targets shows that expectations are no longer uniformly upbeat.
- The bearish case centers on valuation: even with steady demand for household staples, analysts see less room for the stock to rerate higher after its recent move.
- With no major company-specific catalyst in the last week, trading appears tied more to broader consumer staples sentiment and investor preference for defensive names than to fresh operating news.

Kimberly-Clark is drawing cautious analyst optimism as the market weighs steady fundamentals against limited near-term catalysts.
- Analyst sentiment is mostly neutral to mildly positive, which suggests investors see Kimberly-Clark as a steady defensive name rather than a fast-growth story.
- The stock’s appeal is being tied to resilient household and personal-care demand, which can help support earnings even when broader consumer spending softens.
- Recent forecast commentary points to valuation-supported upside, but the range of estimates remains wide, showing that the market is still debating how much growth the business can deliver.

Colgate-Palmolive is sliding on valuation worries as analysts flag limited upside and a possible 8% downside.
- Recent analyst commentary has been mixed to mildly positive overall, but the spread between the highest and lowest targets shows that expectations are no longer uniformly upbeat.
- The bearish case centers on valuation: even with steady demand for household staples, analysts see less room for the stock to rerate higher after its recent move.
- With no major company-specific catalyst in the last week, trading appears tied more to broader consumer staples sentiment and investor preference for defensive names than to fresh operating news.

Kimberly-Clark is drawing cautious analyst optimism as the market weighs steady fundamentals against limited near-term catalysts.
- Analyst sentiment is mostly neutral to mildly positive, which suggests investors see Kimberly-Clark as a steady defensive name rather than a fast-growth story.
- The stock’s appeal is being tied to resilient household and personal-care demand, which can help support earnings even when broader consumer spending softens.
- Recent forecast commentary points to valuation-supported upside, but the range of estimates remains wide, showing that the market is still debating how much growth the business can deliver.
Investment Analysis
Pros
- Colgate-Palmolive's revenue increased by over 3% in 2024 to $20.1 billion, showing steady top-line growth.
- The company has a strong dividend yield of approximately 2.7%, providing consistent income to investors.
- Colgate-Palmolive benefits from a diversified product portfolio spanning oral care, personal care, home care, and pet nutrition.
Considerations
- The stock trades at a relatively high price-to-earnings ratio around 21.5, which may indicate overvaluation versus peers.
- Colgate-Palmolive has a higher debt-to-equity ratio that could imply greater financial leverage risks.
- The company's stock price has shown limited appreciation over the past year, suggesting growth limitations in current market conditions.
Pros
- Kimberly-Clark is ranked highly on fundamental stock indicators, reflecting strong financial health and operational performance.
- The company has moderate correlation with Colgate-Palmolive, offering potential portfolio diversification benefits.
- Kimberly-Clark maintains a solid market capitalization near $44 billion, supporting its stable industry position.
Considerations
- Kimberly-Clark’s year-to-date and annual stock performance have been lower compared to Colgate-Palmolive, indicating weaker recent momentum.
- The stock shows moderate beta and volatility, which may lead to higher risk than more defensive consumer staple peers.
- Limited recent growth catalysts have constrained Kimberly-Clark’s ability to outpace competitors in consumer goods.
Colgate-Palmolive (CL) Next Earnings Date
Colgate-Palmolive’s next earnings release is expected on July 31, 2026, based on the company’s usual late-July reporting pattern. The upcoming report should cover Q2 2026. If management confirms the date formally, it will likely be announced closer to the release window.
Kimberly-Clark (KMB) Next Earnings Date
The next expected earnings date for KMB is August 7, 2026, based on current market estimates and its typical reporting pattern. The upcoming release should cover Q2 2026 results. This date is still an estimate, as Kimberly-Clark has not formally confirmed the announcement schedule.
Colgate-Palmolive (CL) Next Earnings Date
Colgate-Palmolive’s next earnings release is expected on July 31, 2026, based on the company’s usual late-July reporting pattern. The upcoming report should cover Q2 2026. If management confirms the date formally, it will likely be announced closer to the release window.
Kimberly-Clark (KMB) Next Earnings Date
The next expected earnings date for KMB is August 7, 2026, based on current market estimates and its typical reporting pattern. The upcoming release should cover Q2 2026 results. This date is still an estimate, as Kimberly-Clark has not formally confirmed the announcement schedule.
Buy CL or KMB in Nemo
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.


